Literature DB >> 9244806

Functional NF-IL6/CCAAT enhancer-binding protein is required for tumor necrosis factor alpha-inducible expression of the granulocyte colony-stimulating factor (CSF), but not the granulocyte/macrophage CSF or interleukin 6 gene in human fibroblasts.

G Adler.   

Abstract

Entities:  

Year:  1997        PMID: 9244806      PMCID: PMC2198959          DOI: 10.1084/jem.186.1.171

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


× No keyword cloud information.
Retraction: Kiehntopf, M., F. Herrmann, and M.A. Brach. 1995. Functional NF-IL6/CCAAT enhancer-binding protein is required for tumor necrosis factor α-inducible expression of the granulocyte colony-stimulating factor (CSF), but not the granulocyte/macrophage CSF or interleukin 6 gene in human fibroblasts. J. Exp. Med. 181:793–798. The Editorial Board of The Journal of Experimental Medicine regrets to inform its readership that due to scientific misconduct, the results of the above named paper are not valid. A letter dated April 30, 1997 was received from Guido Adler, M.D., the Dean of the School of Medicine at the University of Ulm. In his letter, Dr. Adler states that “fraud was uncovered in the laboratory of Friedhelm Herrmann and Marion Brach. In a series of papers major results were fabricated [including]: . . . Kiehntopf M, Herrmann F, Brach M. J. Exp. Med. 181, 793, 1995.” In addition to his letter, a signed statement from each of the authors agreeing to the retraction of this article is on file at Rockefeller University Press. The Editors
  2 in total

1.  More prickly pear, a second class acquittal.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2004-04-07       Impact factor: 4.599

2.  CSF-induced and HIV-1-mediated distinct regulation of Hck and C/EBPbeta represent a heterogeneous susceptibility of monocyte-derived macrophages to M-tropic HIV-1 infection.

Authors:  Iwao Komuro; Yasuko Yokota; Sachiko Yasuda; Aikichi Iwamoto; Kiyoko S Kagawa
Journal:  J Exp Med       Date:  2003-08-04       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.